Apr 20, 2020
|
Vertex to Announce First-Quarter 2020 Financial Results on April 29
|
|
Apr 07, 2020
|
The Vertex Foundation Commits $5 Million to Support Global COVID-19 Pandemic Response
|
|
Apr 07, 2020
|
The Vertex Foundation Donates $300,000 to Support COVID-19 Relief Efforts in the Most Vulnerable Massachusetts Communities
|
|
Mar 27, 2020
|
Vertex Confirms Supply Chain Continuity and Business Outlook for Its Cystic Fibrosis Medicines and Provides Initial Update on Development Programs
|
|
Mar 13, 2020
|
The Vertex Foundation Donates $500,000 to Partners HealthCare to Support COVID-19 Outbreak Response
|
|
Mar 09, 2020
|
Vertex Confirms Supply Chain Continuity and 2020 Business Outlook
|
|
Mar 02, 2020
|
Vertex Announces Cancellation of its March 3 Presentation at the Cowen Health Care Conference
|
|
Feb 25, 2020
|
Vertex Announces Availability of Cystic Fibrosis Medicine KALYDECO® (ivacaftor) in New Zealand
|
|
Feb 25, 2020
|
Vertex to Present at the Cowen Health Care Conference on March 3
|
|
Jan 30, 2020
|
Vertex Reports Full-Year and Fourth-Quarter 2019 Financial Results
|
|
Jan 21, 2020
|
Vertex to Announce Full-Year and Fourth-Quarter 2019 Financial Results on January 30
|
|
Jan 08, 2020
|
Vertex to Present at the J.P. Morgan Healthcare Conference on January 13
|
|
Dec 13, 2019
|
Vertex and Republic of Ireland Expand Long-Term Cystic Fibrosis Medicines Reimbursement Agreement to Include Triple Combination Therapy for All Eligible Patients Ages 12 and Over Once Licensed
|
|
Dec 10, 2019
|
Vertex Announces European Commission Approval for KALYDECO® (ivacaftor) in Infants With Cystic Fibrosis Ages 6 Months to Less Than 12 Months With Certain Mutations in the CFTR Gene
|
|
Nov 20, 2019
|
French Authorities Approve National Reimbursement of ORKAMBI® (lumacaftor/ivacaftor) for Eligible People Ages Two and Older With Cystic Fibrosis
|
|
Nov 19, 2019
|
CRISPR Therapeutics and Vertex Announce Positive Safety and Efficacy Data From First Two Patients Treated With Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001® for Severe Hemoglobinopathies
|
|
Nov 18, 2019
|
Vertex and Molecular Templates Establish Collaboration to Discover and Develop Novel Targeted Conditioning Regimens to Enhance Hematopoietic Stem Cell Transplants
|
|
Nov 13, 2019
|
Vertex Confirms Wales Offer Accepted for Access to All Licensed Cystic Fibrosis Medicines
|
|
Nov 12, 2019
|
Vertex Confirms Northern Ireland Offer Accepted for Cystic Fibrosis Medicines
|
|
Nov 07, 2019
|
Vertex to Present at the Credit Suisse Healthcare Conference on November 12
|
|